<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5907">
  <stage>Registered</stage>
  <submitdate>19/02/2015</submitdate>
  <approvaldate>19/02/2015</approvaldate>
  <nctid>NCT02379845</nctid>
  <trial_identification>
    <studytitle>NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall</studytitle>
    <scientifictitle>MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NBTXR3-301</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adult Soft Tissue Sarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - NBTXR3
Treatment: devices - Radiation therapy

Experimental: Arm A - NBTXR3 + Radiotherapy

Active Comparator: Arm B - Radiotherapy alone


Treatment: devices: NBTXR3
One intratumor implantation by injection

Treatment: devices: Radiation therapy
5 weeks/50 Gy (5 x 2 Gy by week)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pathological Complete Response Rate (pCRR) - To compare antitumor activity in terms of Pathological complete response rate (pCRR) of intratumor injection of NBTXR3 activated by external beam radiation therapy (EBRT), versus EBRT alone</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of early and late TEAE, post-TEAE, SAE and laboratory abnormalities (NCI CTCAE V4.0)</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR) by Imaging (MRI) according to RECIST 1.1</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor volume changes (theoretical tumor volume estimated as: Lenght x Width x Depth</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resection Margins (R0, R1, R2)</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Limb amputation rate</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age: 18 years and older

          -  Locally Advanced Soft Tissue Sarcoma of the Extremity and Trunk Wall

          -  All grades, including Locally advanced unresectable low grade tumor

          -  Candidate to radiotherapy i.e. unresectable tumor or unfeasible carcinological
             surgery:

               -  Primary tumor or,

               -  Relapsed tumor, localized out of previously irradiated area

          -  WHO performance score 0 to 2

          -  Adequate function of bone marrow

          -  Adequate renal function

          -  Adequate hepatic function

          -  Adequate pulmonary function

          -  All female patients of childbearing potential must have a negative serum/urinary
             pregnancy test</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Absence of written Informed Consent duly signed and dated

          -  Patients with the following histological type: embryonal or alveolar rhabdomyosarcoma,
             Ewing's sarcoma, osteosarcoma or chondrosarcoma, Kaposi's sarcoma, primitive
             neuroectodermal tumor, angiosarcoma, aggressive fibromatosis or dermatofibrosarcoma
             protuberans

          -  Soft Tissue Sarcoma of the Trunk Wall localized in the abdominal region i.e. the
             region defined cranially by the xiphoid process of the sternum and the costal margins,
             and caudally by the line joining the anterior superior iliac spines, both limited by
             the perpendicular lines crossing both nipples

          -  Metastatic disease (CT-scan / MRI verification) with life expextancy shorter than 6
             months

          -  Previous radiation therapy in relapse site of soft tissue sarcoma (no radiation
             re-chanllenge is permitted)

          -  Concurrent treatment with any other anticancer therapy, including chemotherapy,
             immunotherapy, targeted therapy, gene therapy, or patients planning to receive these
             treatments during the study

          -  Absence of histologically or cytologically proven cancer at the first diagnosis

          -  Previous neoadjuvant chemotherapy treatment given as an upfront of the current
             treatment line

          -  Hemolytic anemia

          -  Autoimmune disease

          -  Complete initial work up earlier than 4 weeks prior to patient registration

          -  Patients unable to comply with scheduled visites, treatment plans, laboratory tests,
             and other study procedures

          -  Patients participating in another clinical investigation at the time of signature of
             the informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Capital Region Cancer Service, Canberra Hospital - Canberra</hospital>
    <hospital>Chris O'Brien Lifehouse - Sydney</hospital>
    <postcode> - Canberra</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ghent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Herblain</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cebu City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Pasig City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Quezon City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Floresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Oradea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Targu Mures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>George</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Nanobiotix</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>PharmaEngine</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Radiation therapy given before surgery of soft tissue sarcoma decreases the size
      of the tumor mass and the presence of malignant cells in its peripheral region. NBTXR3 and
      radiation therapy may kill more cancer cells and increase the tumor shrinkage rendering
      surgery more feasible or easier and achieve better local control of the tumor.

      PURPOSE: This phase II/III is a prospective randomized, multi-center, open-label and active
      controlled two arms study in patients with locally advanced soft tissue sarcoma (STS) of the
      extremity and trunk wall. Patients will be randomized to receive either NBTXR3 as intratumor
      injection, activated by external beam radiation therapy or external beam radiation therapy
      alone, as preoperative treatment. Once the radiotherapy treatment is completed, tumor surgery
      will be performed in all patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02379845</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Mikaela DIMITRIU, PhD</name>
      <address />
      <phone />
      <fax />
      <email>mikaela.dimitriu@nanobiotix.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>